LEARNING POINTS/TAKE HOME MESSAGES

We hope readers can appreciate that cPAN is a distinct entity different to sPAN, with a more benign clinical course. The risk of progression from cPAN to sPAN remains unclear, albeit slow. Prompt recognition of this rare condition is required to prevent permanent neurological deficit and scarring. In terms of management, cPAN is steroid responsive and steroid sparing agents are effective to prevent relapse.